Announced Positive Top-Line Phase 1 MAD Trial Results for DA-1726 in Obesity, Demonstrating Compelling Weight Loss and Best-in-Class Potential for Glucose Control, ...

During the quiet hours of sleep, your brain is hard at work. It sends out tiny electrical signals that ripple across networks ...

Company had a strong start to 2025, emerging as an R&D-focused organization Exclusive license agreement with Novo Nordisk for LX9851 executed; IND-enabling studies on track for completion in 2025 Phas ...

HEPZATO launch shows strong revenue growth, profitability, and U.S. expansion, marking a biotech turning point. Read why DCTH ...